CRXT CLARUS THERAPEUTICS HLDGS INC

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes.

Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics’ website at .

About Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit  and . Follow us on Twitter () and LinkedIn ().

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Investor Relations Contact:

Kara Stancell

Vice President, Investor Relations & Corporate Communications



(847) 562-4300 x 206



EN
12/05/2022

Underlying

CRXTCLARUS THERAPEUTICS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CLARUS THERAPEUTICS HLDGS INC

 PRESS RELEASE
Free
CRXT CLARUS THERAPEU...

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for...

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeu...

October 18, 2022 1 EN
 PRESS RELEASE
Free
CRXT CLARUS THERAPEU...

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale o...

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc.,...

September 6, 2022 1 EN
 PRESS RELEASE
Free
CRXT CLARUS THERAPEU...

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operatin...

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing soluti...

August 18, 2022 1 EN
 PRESS RELEASE
Free
CRXT CLARUS THERAPEU...

Clarus Therapeutics Announces Notice of Allowance for Additional Paten...

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a ...

July 28, 2022 1 EN
 PRESS RELEASE
Free
CRXT CLARUS THERAPEU...

Clarus Therapeutics to Present New Data for JATENZO® (testosterone und...

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for J...

June 9, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch